All In Biotech

Drug Trial Radar · NCT07775287

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

A Randomized, Open-label, Phase 3 Trial of Petosemtamab + FOLFIRI/mFOLFOX6 Versus Cetuximab or Bevacizumab + FOLFIRI/mFOLFOX6 as Second-line Treatment in Participants With RAS and BRAF Wild-type, Recurrent, Unresectable or Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 7, 2026

Primary completion

Mar 30, 2029

Study completion Jan 31, 2030

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or doctor's choice of standard-of-care (SOC) cetuximab or bevacizumab + chemotherapy (mFOLFOX6 or FOLFIRI). No participants will be given placebo. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 2 visits at the study clinic for each cycle (duration of cycle is 4 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.

Conditions

  • Colorectal Cancer

Interventions

  • PetosemtamabDrug

    Intravenous (IV) infusion.

  • CetuximabDrug

    IV infusion.

  • BevacizumabDrug

    IV infusion.

  • 5-FUDrug

    IV infusion.

  • Leucovorin (Calcium Folinate)Drug

    IV infusion.

  • OxaliplatinDrug

    IV infusion.

  • IrinotecanDrug

    IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 2.5 years
  2. Objective Response Rate (ORR) per RECIST v1.1 as Assessed by BICRTime frame: Up to approximately 2.5 years

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Genesis Cancer Center Hot Springs National Park

    Hot Springs, Arkansas · Recruiting

  • Valkyrie Clinical Trials - Los Angeles

    Los Angeles, California · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Low Country Cancer Care Associates_Savannah_2

    Savannah, Georgia · Recruiting

  • New York Cancer and Blood Specialists - Babylon Medical Oncology

    Babylon, New York · Recruiting

  • Vista Oncology - West Olympia_Olympia_2

    Olympia, Washington · Recruiting

  • PanOncology

    Manati, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.